Q1 2019 13F Holders as of 3/31/2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
115M
-
Number of holders
-
112
-
Total 13F shares, excl. options
-
64.6M
-
Shares change
-
+3.57M
-
Total reported value, excl. options
-
$881M
-
Value change
-
+$50.9M
-
Put/Call ratio
-
0.39
-
Number of buys
-
63
-
Number of sells
-
-42
-
Price
-
$13.64
Significant Holders of Coherus Oncology, Inc. - Common Stock (CHRS) as of Q1 2019
133 filings reported holding CHRS - Coherus Oncology, Inc. - Common Stock as of Q1 2019.
Coherus Oncology, Inc. - Common Stock (CHRS) has 112 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 64.6M shares
of 115M outstanding shares and own 55.95% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (7.42M shares), Temasek Holdings (Private) Ltd (6.56M shares), JPMORGAN CHASE & CO (4.74M shares), BlackRock Inc. (4.55M shares), Kohlberg Kravis Roberts & Co. L.P. (3.06M shares), VANGUARD GROUP INC (2.87M shares), Sofinnova Investments, Inc. (2.87M shares), Rubric Capital Management LP (2.64M shares), CITADEL ADVISORS LLC (2.51M shares), and STATE STREET CORP (2.23M shares).
This table shows the top 112 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.